ALLMedicine™ Herpes Zoster Center

Aug 26th, 2021 - At the end of the activity, participants will be able to: • Characterize the burden of herpes zoster infections. • Recommend the recombinant zoster vaccine to patients in accordance with guidance from the Advisory Committee on Immunization Practic...

Dec 1st, 2021 - Key clinical point: Baricitinib maintained a stable safety profile with no new safety signals even with long-term exposure of up to 9. 3 years in patients with active rheumatoid arthritis (RA).

Nov 27th, 2021 - Risk of Herpes Zoster Reactivation After mRNA COVID-19 Vaccination: A Cohort Study.|2021|Birabaharan M,Kaelber DC,Karris MY,|

Nov 25th, 2021 - Infection, chronic pain and depression are considered risk factors for herpes zoster (HZ). However, the correlation between plantar fascial fibromatosis (PFF) and HZ remains unknown. This study investigated HZ risk in patients with PFF. Data was e...

Nov 24th, 2021 - Background Mutations in the Dedicator of Cytokinesis-8 (DOCK8) gene are responsible for an immunodeficiency disease characterized by: severe cutaneous and sinopulmonary infections with bacterial organisms; extensive cutaneous viral infections with...

Dec 7th, 2011 - Although vaccinations are most commonly associated with the pediatric population, it is important for healthcare professionals to be familiar with the vaccines that are recommended for adults. The authors discuss 3 vaccines-the measles, mumps, and...

Jun 12th, 2013 - Neuropathic pain (NP) is often refractory to pharmacologic and noninterventional treatment. On behalf of the International Association for the Study of Pain Neuropathic Pain Special Interest Group, the authors evaluated systematic reviews, clinica...

Jun 6th, 2008 - These recommendations represent the first statement by the Advisory Committee on Immunization Practices (ACIP) on the use of a live attenuated vaccine for the prevention of herpes zoster (zoster) (i.e., shingles) and its sequelae, which was licens...

Nov 24th, 2021 - Background Mutations in the Dedicator of Cytokinesis-8 (DOCK8) gene are responsible for an immunodeficiency disease characterized by: severe cutaneous and sinopulmonary infections with bacterial organisms; extensive cutaneous viral infections with...

Oct 20th, 2021 - The aim of this study is to evaluate the immune response and safety of both GlaxoSmithKline Biologicals SA's (GSK's) herpes zoster (HZ) subunit (su) vaccine in healthy adults 50 years of age (YOA) and older and quadrivalent seasonal influenza (Flu...

Oct 19th, 2021 - Rationale: Vaccination of the older adults is often advised as they are a high-risk population; however, vaccine efficacy generally decreases with age. This is mainly due to a decrease in adaptive immune responses known as immunosenescence, which ...

Oct 4th, 2021 - Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that requires long-term corticosteroid and/or immunosuppressive agents. Thus lupus patients are immunocompromised patients, and the incidence of herpes zoster is higher th...

Sep 13th, 2021 - The purpose of this study is to evaluate the long-term immune responses to the Herpes Zoster subunit (HZ/su) vaccine as well as safety up to 7 years after the 2-dose primary vaccination course from study ZOSTER-041 (NCT02058589). This study will a...

Dec 1st, 2021 - Key clinical point: Baricitinib maintained a stable safety profile with no new safety signals even with long-term exposure of up to 9. 3 years in patients with active rheumatoid arthritis (RA).

Nov 2nd, 2021 - NEW YORK (Reuters Health) - An analysis of Medicare claims data found an increased risk of Guillain-Barre syndrome (GBS) following receipt of the recombinant zoster vaccine (RZV), confirming the same "signal" from the U.S. Centers for Disease Cont...

Nov 1st, 2021 - Risk of Guillain-Barré syndrome (GBS) increased slightly after receiving the recombinant zoster vaccine (RZV; Shingrix), Medicare claims data showed. In the 42 days after vaccination, researchers found approximately three excess GBS cases per mill...

Oct 25th, 2021 - LAS VEGAS, Nevada — An oral Janus kinase 1 (JAK1) inhibitor upadacitinib (Rinvoq, AbbVie) showed high efficacy and good safety as a treatment for ulcerative colitis in a phase 3 trial. The finding could provide some reassurance after the US Food a...

Oct 21st, 2021 - The US Centers for Disease Control and Prevention Advisory Committee of Immunization Practices (ACIP) has voted to recommend Shingrix (Zoster Vaccine Recombinant, Adjuvanted) for the prevention of shingles (herpes zoster) in immunodeficient or imm...